Encephalitis explained Types of encephalitis Infectious encephalitis Enterovirus encephalitis Download PDF Enterovirus encephalitis By Alina Ellerington, Encephalitis Society What are enteroviruses? Each year, a billion or more people worldwide are affected by enteroviruses, more often infants and children. Enterovirus infections are more common in the hotter and wetter months. Enteroviruses are classified into two distinct groups: polioviruses (the common cause of polio) and non-polioviruses (e.g coxsackie A virus, coxsackie B virus, echoviruses, human Enterovirus 71-HEV71). Symptoms Symptoms vary. Most enterovirus infections do not present with symptoms. Others produce mild symptoms such as a short febrile illness with or without a sore throat, vomiting, and on occasions, diarrhoea. Only rarely enterovirus infections result in severe disease in the heart (cardiomyopathy) or nervous system such as meningitis (inflammation of the lining of the brain and spinal cord), acute flaccid paralysis (limb weakness) or encephalitis (inflammation of the brain). Severe enterovirus disease may cause symptoms such as muscle pain, headache, neck stiffness, lethargy, clumsiness. More often people with the severe enterovirus disease present with fever, cough, abdominal pain and gastrointestinal upset and/or rash (especially of the hand, foot and mouth disease) and swollen glands. Diagnosis A doctor may suspect enterovirus infection based on the symptomatology and the risk factors (age, exposure, geographic locations). The diagnosis can be confirmed by using various tests (e.g. identifying the virus in samples taken from the patient: faeces, nose or throat secretions, cerebrospinal fluid (CSF) and/or blood, demonstrating the development of antibodies in blood against enteroviruses). Enterovirus infections of the brain or spinal cord may show on brain scans such as magnetic resonance imaging (MRI). Treatment for non-polio enteroviruses Unfortunately, there is no specific antiviral medication for non-polio enterovirus infection. Treatment consists of supportive measures: antipyretic (to control the fever), analgesic (to control the pain) medication or intensive care therapies in severe cases. Intravenous immune globulin therapy has been used in chronic enterovirus infections in immunocompromised patients (patients with immune system weakened) with some success. Prevention Enteroviruses are very contagious. They spread through fecal-oral, respiratory and oral-to oral routes in crowded environments. For example if you touch hands with an infected person, or touch objects that have the virus on them, or changing nappies or drinking infected water. Perinatal and post-natal transmission from mother to baby can occur. The viruses are very resilient. They can be killed with standard disinfectant and heat, but they are resilient to freezing and chlorine. Enterovirus infections are very difficult to prevent, as many people do not know they are infected. Early diagnosis and effective management of identified cases are good measures of prevention. Careful attention to hand and personal hygiene can help limit outbreaks particularly after contact with secretions from an infected individual. Enteroviruses are a major public health concern given the increase in outbreaks of serious neurological diseases with consequences such as death and disability in survivors. Effective antiviral treatment and vaccination are still required. Vaccines to prevent enterovirus infections and disease are in development with some showing promised in animal models and clinical trials in China. Risk Factors Risk factors associated with enteroviruses infections are: Environmental: poor sanitation and crowded living conditions Age: young children are at a greater risk because of poor hygiene and lack of prior immunity Health: the immuno-compromised also have a high risk for acute infection. Enterovirus encephalitis in newborns (neonatal) Newborns are at a particular risk of developing meningo-encephalitis after infection with enteroviruses. Enterovirus infection in newborns may present with fever, poor-feeding, irritability, lethargy, jaundice, and ‘sepsis’. As well as meningo-encephalitis, newborns can develop pneumonia, hepatitis and myocarditis. In a newborn with symptoms and signs suggestive of possible enterovirus infection, a lumbar puncture should be considered to obtain and examine the CSF. The illness can result in significant brain injury and long-term neurological and developmental problems. Human Enterovirus 71 (HEV71) HEV71 was first identified in 1969, causing large epidemics in Bulgaria, Hungary, Malaysia and Taiwan. In the late 1990s, HEV71 emerged in eastern Asia causing large outbreaks of hand-foot-mouth disease (HFMD) and fever, and, in some children, meningitis, acute flaccid paralysis and a severe brainstem encephalitis with high mortality (death). Children with brainstem encephalitis usually present with myoclonus (quick, involuntary muscle jerk), tremor, ataxia (co-ordination, balance and speech difficulties), nystagmus (involuntary eye movement) and cranial nerve palsies. The outcomes of brainstem encephalitis are severe, only a few children recovering fully, most of them are left with permanent neurological sequelae. HEV71 epidemics have caused great public health concern because of their size and the risk of children younger than five years old developing severe neurological disease and potentially death. The largest epidemic occurred in China, beginning in 2007, with reports of almost 500,000 cases in 2008, increasing to over 1.7 million cases in 2010, and close to 1000 deaths during the epidemic. HEV71 epidemics are seasonal, with the highest transmission rates occurring during warmer, wetter months. A comprehensive guide for clinical management of HFMD has recently been published by the World Health Organization. Infection control practices consist mainly of hand washing, disinfection, and isolation during epidemics. A major effort has gone into developing vaccines for HEV71, particularly in China, with three large trials now completed and published in 2014. While this provides hope for future control HEV71 epidemics, at this stage, the trialled vaccines are proven to work only for one sub-type of the HEV71. There is a need to determine enterovirus subtypes causing disease around the globe, to test the current HEV71 vaccines against other subtypes, and to develop vaccines with broader protection for the many sub-types of HEV71 and for the development of potent antiviral treatments for children and adults who acquire this potentially devastating infection FS042V1 Enterovirus encephalitis Page created: February 2015/ Review date: February 2018 Disclaimer: If you would like more information on the source material the author used to write this document please contact the Encephalitis Society. None of the authors of the above document has declared any conflict of interest which may arise from being named as an author of this document.